Bullish indicating open at $55-$60, IPO prices at $37
NEW YORK - Indaptus Therapeutics, Inc. (NASDAQ:INDP), a clinical-stage biotechnology company with a market capitalization of $11.1 million, has shared new pharmacodynamic findings from its ongoing Phase 1 trial of Decoy20, a novel cancer immunotherapy agent. The latest results from the weekly dosing cohort show that Decoy20 is generally well-tolerated and has led to immune cell trafficking, a key process in effective anticancer immune response. According to InvestingPro data, the company maintains a strong liquidity position with more cash than debt on its balance sheet, though its overall financial health score remains challenged at 1.62.
The company, which focuses on developing treatments for cancer and viral infections, reported that more than 20 patients have been enrolled in this cohort, reaching an important milestone. Initial data suggest a favorable safety profile for Decoy20 at a 30 million cell dose, with some patients showing stable disease. While the stock has experienced a significant decline of about 45% over the past six months, analysts maintain optimistic price targets ranging from $5 to $12, suggesting potential upside. Get deeper insights and access to more than 5 additional ProTips with InvestingPro.
Decoy20 has been observed to cause short-term increases in immune system biomarkers, such as cytokines and chemokines, which are vital for activating the body’s defenses against cancer. The new insights reveal that weekly treatment with Decoy20 results in broad, blood-based immune cell movement, including weekly fluctuations in major innate and adaptive immune cell types. This indicates active mobilization of immune cells from bone marrow or their trafficking to tissues.
Michael Newman, Founder and Chief Scientific Officer of Indaptus, stated, "Immune cell movement – or trafficking to and from tissues, tumors, and bone marrow – is critical for successful anti-tumor therapy." He expressed encouragement by the consistency of these effects with each week of dosing and looks forward to further assessing their impact on tumor response.
The company has also initiated a new arm of its Phase 1b/2 clinical trial to evaluate Decoy20 in combination with BeiGene’s PD-1 checkpoint inhibitor, tislelizumab, focusing on safety, dose optimization, and preliminary anti-tumor activity.
Indaptus’s approach leverages its patented technology, which involves single strains of attenuated and killed non-pathogenic Gram-negative bacteria. This technology aims to activate both innate and adaptive immune cells and pathways, potentially enhancing the effectiveness of existing cancer treatments.
The press release contains forward-looking statements about the expected effects of Decoy20 and the company’s plans for clinical trials. These statements are subject to risks and uncertainties that could cause actual results to differ materially. The information provided is based on a press release statement. With current earnings forecasts suggesting continued losses and a return on invested capital of -162%, investors should conduct thorough due diligence. InvestingPro subscribers can access comprehensive financial analysis, including detailed Fair Value estimates and health scores, to make more informed investment decisions.
In other recent news, Indaptus Therapeutics, Inc. announced the progression of an expansion arm in its Phase 1b/2 clinical trial, evaluating the safety and preliminary anti-tumor activity of Decoy20 in combination with BeiGene’s PD-1 inhibitor, tislelizumab. This trial is part of efforts to optimize dosing and observe early signs of efficacy in patients with advanced solid tumors. Additionally, Indaptus has secured new patents in China, Japan, and Israel for its Decoy platform, which is used in the prevention and treatment of Hepatitis B and HIV. These patents highlight the potential of Indaptus’s approach to addressing chronic infectious diseases. The company has also received authorization from Health Canada to extend its U.S. clinical trial for Decoy20 to Canadian sites, aiming to accelerate patient enrollment and enhance research for treating solid tumors. CEO Jeffrey Meckler expressed enthusiasm about the inclusion of Canadian investigators and patients, anticipating a more diverse data set. Indaptus’s Decoy platform is designed to activate both innate and adaptive immune responses and has shown promise in preclinical studies against various cancers and chronic viral infections. These developments underscore Indaptus’s ongoing efforts in advancing treatments for cancer and infectious diseases.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.